Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
03 November 2021 - 1:00PM
Business Wire
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the
appointment of Stewart Campbell as Executive Vice President and
President of North America, effective immediately. Based in
Cambridge, he will lead the business in the US and Canada,
continuing to drive Ipsen’s positive impact for patients. He will
report directly to David Loew, CEO, Ipsen and serve on the
Executive Leadership Team (ELT).
“Stewart brings extensive experience in the pharmaceutical
industry which will be instrumental in accelerating Ipsen’s growth
in North America as we continue to strengthen our global footprint
and deliver our new group strategy, Focus. Together. For patients
and society. We are delighted to welcome him to the ELT, and we
look forward to working closely with him,” said David Loew, CEO,
Ipsen.
“I’m excited to be appointed as EVP and President of North
America at this key moment for Ipsen,” said Stewart Campbell. “I’ve
been impressed by the dedication that I’ve seen from all of Ipsen
as we work together to improve the lives of patients and their
families. I am looking forward to helping write the next chapter of
our story in North America.”
Stewart joined Ipsen as Senior Vice President and Franchise Head
of Oncology earlier in 2021 from Roche/Genentech where he spent
more than 14 years and was responsible for the lifecycle management
of some of Roche’s oncology blockbusters, including both commercial
and clinical development globally. Through a career of more than 20
years in the pharmaceutical industry, Stewart has gained deep
experience leading country and global commercial functions in
Oncology and Specialty Care markets, including in Canada,
Switzerland and the US.
Stewart is a graduate of Concordia University in Montreal,
Canada, where he received his B.S. in physiology with a minor in
physics. He received an MBA in corporate finance from Queens
University in Kingston, Canada and an additional MBA in business
strategy from the Johnson School of Management at Cornell
University in Ithaca, New York.
Ipsen North America
Ipsen is a global biopharmaceutical company focused on
innovation and specialty care. Its resources, investment and energy
center on discovering, developing and commercializing medicines in
three key therapeutic areas – Oncology, Rare Disease and
Neuroscience. The Company is dedicated to providing hope for
patients whose lives are challenged by unmet medical needs. Ipsen’s
North American operations are located in Cambridge, Massachusetts,
one of the Company’s three global hubs. For more information,
please visit www.ipsenus.com.
Forward-looking statements
The forward-looking statements, objectives and targets contained
herein are based on Ipsen’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events
to differ materially from those anticipated herein. All of the
above risks could affect Ipsen’s future ability to achieve its
financial targets, which were set assuming reasonable macroeconomic
conditions based on the information available today. Use of the
words ‘believes’, ‘anticipates’ and ‘expects’ and similar
expressions are intended to identify forward-looking statements,
including Ipsen’s expectations regarding future events, including
regulatory filings and determinations. Moreover, the targets
described in this document were prepared without taking into
account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives
are based on data and assumptions regarded as reasonable by Ipsen.
These targets depend on conditions or facts likely to happen in the
future, and not exclusively on historical data. Actual results may
depart significantly from these targets given the occurrence of
certain risks and uncertainties, notably the fact that a promising
medicine in early development phase or clinical trial may end up
never being launched on the market or reaching its commercial
targets, notably for regulatory or competition reasons. Ipsen must
face or might face competition from generic medicine that might
translate into a loss of market share. Furthermore, the research
and development process involves several stages each of which
involves the substantial risk that Ipsen may fail to achieve its
objectives and be forced to abandon its efforts with regards to a
medicine in which it has invested significant sums. Therefore,
Ipsen cannot be certain that favorable results obtained during
preclinical trials will be confirmed subsequently during clinical
trials, or that the results of clinical trials will be sufficient
to demonstrate the safe and effective nature of the medicine
concerned. There can be no guarantees a medicine will receive the
necessary regulatory approvals or that the medicine will prove to
be commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results
may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not
limited to, general industry conditions and competition; general
economic factors, including interest rate and currency exchange
rate fluctuations; the impact of pharmaceutical industry regulation
and healthcare legislation; global trends toward healthcare cost
containment; technological advances, new medicine and patents
attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's
ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the
effectiveness of Ipsen’s patents and other protections for
innovative medicines; and the exposure to litigation, including
patent litigation, and/or regulatory actions. Ipsen also depends on
third parties to develop and market some of its medicines which
could potentially generate substantial royalties; these partners
could behave in such ways which could cause damage to Ipsen’s
activities and financial results. Ipsen cannot be certain that its
partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of
Ipsen’s partners could generate lower revenues than expected. Such
situations could have a negative impact on Ipsen’s business,
financial position or performance. Ipsen expressly disclaims any
obligation or undertaking to update or revise any forward-looking
statements, targets or estimates contained in this press release to
reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so
required by applicable law. Ipsen’s business is subject to the risk
factors outlined in its registration documents filed with the
French Autorité des Marchés Financiers. The risks and uncertainties
set out are not exhaustive and the reader is advised to refer to
Ipsen’s 2020 Universal Registration Document, available on
ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103005117/en/
Media Maryann Quinn
Senior Director, Product Communications, North America
+1-857-529-1151 Maryann.quinn@ipsen.com Investors Craig Marks Vice President,
Investor Relations +44 7584 349 193 Craig.marks@ipsen.com
Ipsen (EU:IPN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ipsen (EU:IPN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024